

Name **Francesco Patti**



Born in Acireale (Italy) 12/06/1958

Scholastic career

II level education 1976

Degree Medicine and Surgery 1982 maximum cum laude

Post Degree Neurology, University of Catania, 1986

Post Degree Physiotherapy, University of Parma, 1990

Work activity

- 1987-1988 Regional fellowship as Junior Neurologist to study “ Descriptive Neuroepidemiology of most frequent neurological diseases in Sicily”, progetto Regionale 55/P, sponsored by WHO.
- 1987–1989 Assisting Professor of Neuroendocrinology and Neuroimmunology Scuola di Specializzazione in Neurologia, University of Catania
- 1991–2000 “Collaboratore Tecnico” Chair of Neurorheabilitation, Institute of Neurological Sciences, University of Catania.
- 2000–2002 “Tecnico Laureato” (Funzionario Tecnico) Department of Neurological Sciences
- November 2002 – October 2014 “Ricercatore Confermato” (Aggregate Professor) Clinical Researcher Department of Neurological Sciences, University of Catania.
- November 2014 - up till now Associate Professor of Neurology, Department of Medical and Surgical Sciences and Advanced Technologies G.F. Ingrassia, University of Catania
- Senior teacher of Neurology at University of Catania, Medicine School since 2014
- Senior teacher of Neurorehabilitation at University of Catania, Physiotherapy degree, since 2002
- Senior teacher of Neurology at University of Catania, Nursing School since 2005
- Director of Magistral Degree Course Science of Rehabilitation of Health Professions 2016-current

Clinician profile and working activities

He is responsible of the tertiary centre of multiple sclerosis at the University of Catania (Italy). He is responsible for diagnostic process, place in therapy and switching therapy (when needed) of each patient. He also works as hub centre in respect to a 3 satellite centers of the same region.

The centre follows more than 3000 patients suffering from Multiple Sclerosis and roughly 100 patients suffering from Devic Disease and Neuromyelitis Optica Spectrum Disorder diseases.

The centre follows also patients suffering from ALS (currently 100 patients) and other people with different forms of spasticity, offering them with a multidisciplinary approach every kind of assistance. More in details for both ALS patients and spasticity patients, he plans rehabilitation program and he is responsible of symptomatic therapies. In this field he realized an intrahospital network opened to territory with other health professionals and of different specializations to make easier living with disabilities of patients

Scientific activity

- Research Interests ;
- Preclinical (1981-1988) ;
- Neurochemistry, Neuroendocrinology, Neuropsychopharmacology ;
- Clinical: (1989-current) ;
- Neuroepidemiology ;
- Clinical Immunology ;
- Quality of Life ;
- Neurorehabilitation ;
- Multiple Sclerosis
- Clinical Trials
- Real world studies
- Symptomatic therapies (i.e. Nabiximols, Levitiracetam, etc)
- Cognitive impairment in Multiple Sclerosis

Author of more than 400 peer reviewed scientific articles of neurochemistry and neuropharmacology, neurology, and more recently of multiple sclerosis (clinical, epidemiology, immunology, treatment, quality of life and rehabilitation). Author of several reviews on different topics in MS research (cognition, adherence, treatment, specific drugs). Scopus H Index score 50, over than 9000 citations, Total IF >1600, mean IF 4.76.

Author of a book "*Il Trattamento multiintegrato sintomatico e riabilitativo della Sclerosi Multipla*".

Referee for the following peer journals: *Quality of life Research, Journal of Neurology, Journal of The Neurological Sciences; Multiple Sclerosis, Journal of Neurology Neurosurgery and Psychiatry, Journal of Neurologic Rehabilitation and Neural Repair, Neurological Sciences, BMC Journals, Lancet Neurology, Neurology, Journal of Neuroimmunology, Multiple Sclerosis International Forum*. He is also associate editor of *Multiple Sclerosis International* and *Multiple Sclerosis and Demyelinating Diseases*. He is section Editor of *BMC Neurology*.

Academic affiliations

- Advisor of Italian Neurological Society (Consigliere della SIN – Società Italiana di Neurologia);
- Advisor of Regional Committee for the PDTA (Percorso diagnostico terapeutico assistenziale) of MS since October 24, 2014;
- Chief of Italian Study Group of Multiple Sclerosis (2017-2021);
- Delegate of European Academy of Neurology, Section Demyelinating Diseases
- Advisor ofECTRIMS (current, since September 2020)
- Member of Italian Study Group of Quality of Life;
- Associate Member of American Academy of Neurology.

Collaborative Multicenter Studies

He is involved in clinical trials activities (phase II, III and observational) in Multiple Sclerosis, NMO and Amyotrophic Lateral Sclerosis in accordance with Good Clinical Practice (SA307JG, RADIANCE, CFTY720D2311, CFTY720D2306, CFTY720D2399, WANT, BREMSO, BEAT, BRAVE DREAMS, BEHAVIOR,VANTAGE, 205-MS-301, 205-MS-201, 205-MS-303, NOVA, LIBERTO, ENSEMBLE, CONSONANCE, Cladfit, Classic, LEMQoL, etc....).

He is national coordinator or NMO committee member of several national and international multicentre studies (Clad fit, ECU-NMO-301, BETA EVAL, RELIEF, COGIMUS, BEACON, Cyclophosphamide, italian use of Immunosuppressive agents, Golden, GAP, etc.....).

He passed GCP course (last certified on 27 jan 2016).

He was funded by FISM for several epidemiological studies on Multiple Sclerosis:

1. Disphagia in MS;
2. Dymus questionnaire on disphagia;
3. Pain in MS;

4. Coexistence of illness and well-being;
5. Validation of short form MSQoL-54;
6. Validation of MS 12 walking test;
7. PENSAMI Phase II study on Palliative care for advanced MS patients.

He was funded by University of Catania, FIR project for the study of "Trace elements and Amyotrophic Lateral Sclerosis".

He is recipient of the following grants

Health Trajectory 2 (Italian Minister) year 2022

Project "Accoglienza" obtained by private funds year 2023

Roche study Opportunity year 2022-2023

Biogen Different scheduling Natalizumab doses administration year 2019-2020

Merck study Clarinet year 2019

BIIT study immunophenotype in multiple sclerosis year 2021-2022

He was inspected by FDA in July 2015 for the study 205-MS-301 (Daclizumab and Multiple Sclerosis): no Form 483 reported.

I authorize the use of my personal data in compliance with Legislative Decree 196/03, GDPR 679/2016/UE and subsequent modifications.

Catania, 25/January/2023

PROF. PATTI FRANCESCO